"MIATA"-minimal information about T cell assays.
Immunotherapy, especially therapeutic vaccination, has a great deal of potential in the treatment of cancer and certain infectious diseases such as HIV (Allison et al., 2006; Fauci et al., 2008; Feldmann and Steinman, 2005). Numerous vaccine candidates have been tested in patients with a variety of tumor types and chronic viral diseases. Often, the best way to assess the clinical potential of these vaccines is to monitor the induced T cell response, and yet there are currently no standards for reporting these results. This letter is an effort to address this problem.
Janetzki
Sylvia
S
Britten
Cedrik M
CM
Kalos
Michael
M
Levitsky
Hyam I
HI
Maecker
Holden T
HT
Melief
Cornelius J M
CJ
Old
Lloyd J
LJ
Romero
Pedro
P
Hoos
Axel
A
Davis
Mark M
MM
D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007118:Immunoassay / Q000592:standards*; D007167:Immunotherapy; D015166:Monitoring, Immunologic / Q000592:standards*; D009369:Neoplasms / Q000628:therapy*; D017410:Practice Guidelines as Topic / Q000592:standards*; D013601:T-Lymphocytes / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology / Q000627:therapeutic use*; D014777:Virus Diseases / Q000628:therapy*
D019496:Cancer Vaccines; D014765:Viral Vaccines